In clinical practice, migraine management is strictly divided into two categories: abortive treatments taken at the onset of an attack to stop pain, and preventive therapies taken daily to lower attack frequency. Standard preventive drugs historically included beta-blockers, anti-seizure medications like topiramate, or antidepressants. However, a persistent question in headache research was whether a single drug mechanism could successfully serve both acute and preventive roles.
To test this hypothesis, researchers conducted a landmark Phase 2 trial examining the CGRP receptor antagonist telcagepant as a daily preventive agent. The trial enrolled adult patients who had experienced migraine with or without aura for over a year and averaged 3 to 14 migraine days per month. Participants were divided to receive twice-daily doses of telcagepant (140 mg or 280 mg) or a placebo over a 12-week period.
The efficacy results from the available trial data were highly encouraging. At the one-month mark, patients receiving daily telcagepant experienced a noticeable reduction in total monthly headache days and migraine-specific days compared to placebo. On average, patients taking the 280 mg twice-daily regimen reduced their monthly headache days by roughly 3.1 days from baseline, outperforming the placebo group's 1.7-day reduction. Furthermore, approximately 36% of patients on telcagepant achieved a 50% or greater reduction in monthly headache days, nearly double the responder rate seen in the placebo arm.
These numbers mirrored the therapeutic efficacy typically observed with gold-standard preventives like topiramate. Beyond reducing overall headache frequency, the study showed a decrease in monthly migraine attacks and a reduced need for acute rescue medications.
The clinical takeaway was profound: CGRP is not merely a marker released during an acute attack, but a core ongoing driver of migraine susceptibility. Blocking the CGRP pathway continuously demonstrated that single-target receptor antagonism could prevent attacks before they start.
Although this specific oral trial was cut short due to off-target hepatic side effects, it provided the definitive proof-of-concept that CGRP pathway modulation works for prevention. This breakthrough directly paved the way for the modern targeted preventive therapies used in neurology clinics today.